Emergex logo.png
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
June 30, 2021 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...
Emergex logo.png
Emergex Strengthens Senior Management Team
February 23, 2021 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Strengthens Senior Management Team             Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon,...
Emergex logo.png
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
January 05, 2021 07:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...
Emergex logo.png
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
January 05, 2021 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...
Emergex logo.png
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
November 18, 2020 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases Investor support further endorsement of vaccine development strategy...
Emergex logo.png
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
September 15, 2020 07:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...
Emergex logo.png
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
September 15, 2020 02:00 ET | Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...